Researchers studying pancreatic cancer say they have new clues to why some breakthrough drugs eventually stop working.

The findings come from laboratories in Massachusetts, according to the article.

Scientists mapped genetic shifts during long drug treatment that help explain how drug tolerance develops.

The work covers escape routes inside tumors and protein changes linked to treatment failure.

Researchers are also looking at drug combinations meant to keep an initial treatment effective longer.

The article says AIM ImmunoTech is exploring Ampligen as a complement to emerging pancreatic cancer therapies.

Teams in the United States are designing new trial plans from the lab work, with patient-safety rules still in place.

The article says human studies could begin in the coming months to test whether added compounds delay resistance.

Read the full story on the pancreatic cancer resistance findings from the Massachusetts labs.